234 related articles for article (PubMed ID: 27620069)
1. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Sharma S; Taliyan R
Pharmacol Res; 2016 Nov; 113(Pt A):320-326. PubMed ID: 27620069
[TBL] [Abstract][Full Text] [Related]
2. Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues.
Kumar KK; Aburawi EH; Ljubisavljevic M; Leow MKS; Feng X; Ansari SA; Emerald BS
Clin Epigenetics; 2024 Jun; 16(1):78. PubMed ID: 38862980
[TBL] [Abstract][Full Text] [Related]
3. Repression of Transcriptional Activity of Forkhead Box O1 by Histone Deacetylase Inhibitors Ameliorates Hyperglycemia in Type 2 Diabetic Rats.
Cho HM; Seok YM; Lee HA; Song M; Kim I
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424007
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of histone deacetylase 3 (
Sathishkumar C; Prabu P; Balakumar M; Lenin R; Prabhu D; Anjana RM; Mohan V; Balasubramanyam M
Clin Epigenetics; 2016; 8():125. PubMed ID: 27904654
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities.
Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM
Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383
[TBL] [Abstract][Full Text] [Related]
6. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
Bush EW; McKinsey TA
Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
[TBL] [Abstract][Full Text] [Related]
7. HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice.
Zhao Q; Zhang F; Yu Z; Guo S; Liu N; Jiang Y; Lo EH; Xu Y; Wang X
J Neuroinflammation; 2019 May; 16(1):103. PubMed ID: 31101061
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Meier BC; Wagner BK
Epigenomics; 2014 Apr; 6(2):209-14. PubMed ID: 24811789
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells.
Kawada Y; Asahara SI; Sugiura Y; Sato A; Furubayashi A; Kawamura M; Bartolome A; Terashi-Suzuki E; Takai T; Kanno A; Koyanagi-Kimura M; Matsuda T; Hashimoto N; Kido Y
PLoS One; 2017; 12(9):e0184435. PubMed ID: 28886131
[TBL] [Abstract][Full Text] [Related]
10. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
12. Role of HDAC inhibitors in diabetes mellitus.
Makkar R; Behl T; Arora S
Curr Res Transl Med; 2020 Apr; 68(2):45-50. PubMed ID: 31477543
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential for HDAC inhibitors in the heart.
McKinsey TA
Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors: A new promising drug class in anti-aging research.
Pasyukova EG; Vaiserman AM
Mech Ageing Dev; 2017 Sep; 166():6-15. PubMed ID: 28843433
[TBL] [Abstract][Full Text] [Related]
15. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T
Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Marks PA
Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
[TBL] [Abstract][Full Text] [Related]
19. Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors.
Galán M; Varona S; Orriols M; Rodríguez JA; Aguiló S; Dilmé J; Camacho M; Martínez-González J; Rodriguez C
Dis Model Mech; 2016 May; 9(5):541-52. PubMed ID: 26989193
[TBL] [Abstract][Full Text] [Related]
20. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
Eom GH; Kook H
Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
